Recent guidelines also recommend against treating IPF with corticosteroids, colchicine, cyclosporine A, combination corticosteroid and immunomodulator therapy, interferon-, bosentan, or etanercept [2]

Recent guidelines also recommend against treating IPF with corticosteroids, colchicine, cyclosporine A, combination corticosteroid and immunomodulator therapy, interferon-, bosentan, or etanercept [2]. 1b trial, intravenous injections of a recombinant version of the normal human serum protein Serum Amyloid P (SAP, also known as PTX2) improved lung function in IPF individuals. Keywords:Fibrosing, Lung, Fibrocyte, Macrophage, Clinical tests, Modulation, Idiopathic pulmonary fibrosis, Treatment, Therapeutics, Salt intake == Intro == Idiopathic pulmonary fibrosis (IPF), also referred to as typical interstitial pneumonia (UIP), is definitely a devastating disease that, until recently, was essentially untreatable. Like asthma, it generally presents as shortness of breath, but the ~130,000 IPF individuals in the US tend to become older, have relatively few flare-ups, and show a steady decrease in lung function with ~80% mortality 5 years after the initial diagnosis [1]. Chest X-rays display diffuse increased denseness in the lungs, and high-resolution CT scans display a honeycomb-like set up of dense cells forming in the lungs, with increased denseness typically in the periphery of the base of the lung [2]. The analysis Lathosterol however can be hard and requires a careful exclusion of additional possible lung diseases [2,3]. Lung biopsies, the original gold standard for analysis (but now performed less frequently given the evolving part of high resolution CT scans, as well as the potential for this invasive diagnostic process to exacerbate lung damage) display scar-tissue like lesions in the alveoli that demonstrate Lathosterol the usual interstitial pneumonia pattern of relatively preserved lung cells, founded fibrosis, and intervening areas of active fibrogenesis called fibroblastic foci. There is a relatively small genetic component, and the lung function decline rate varies from patient to patient. Although some IPF is probably due to exposure to particulate irritants such as coal dust, the cause in many patients is unknown. Oxygen therapy and lung transplants remain a recommended Lathosterol treatment [2]. == New developments in the biology of IPF == == IPF is usually one of many RCBTB1 different fibrosing diseases == Fibrosis involves the inappropriate formation of scar tissue-like lesions in tissues. Examples of fibrosing diseases include end-stage kidney disease, cardiac fibrosis, hypertrophic scarring, cirrhosis of the liver, and of course IPF. Fibrosis also occurs in asthma, causing a thickening of the airway walls [4], whereas in IPF the fibrosis is usually less in the airway walls and more Lathosterol around the alveoli. A growing awareness in the IPF field is usually that IPF has strong similarities to other fibrosing diseases. A 2009 Keystone meeting on fibrosis was, for some workers in the IPF field, their first chance to meet people working on related diseases such as cardiac and renal fibrosis. As with asthma, the consensus in the field is usually that fibrosis is due to an overreaction by a tissue defense/repair mechanism to a relatively minor insult. == Specialized profibrotic macrophages potentiate fibrosis == In animal models, cells of the innate immune system also participate in fibrosis. Monocytes leave the circulation, enter the lesion, and can differentiate Lathosterol into macrophages. The current consensus is usually that in rodents and humans there are at least three basic types of macrophages [5]. M1 macrophages participate in the defense against bacteria and participate in inflammation; alternatively activated (M2a) macrophages participate in fibrosis [6,7]; while Mreg macrophages are regulatory and help to suppress inflammation and fibrosis [8]. A key problem in the macrophage field is usually that until very recently, most workers lumped M2a and Mreg macrophages together into a category called M2, and much of the earlier literature does not distinguish between the very different M2a and Mreg macrophages. == Many of the lesion cells appear to originate from resident fibroblasts == The source of the cells that form fibrotic lesions has been an active area of research [9]. Many of the lesion cells have characteristics of mesenchymal cells, express unusual markers including -easy muscle actin, and secrete copious amounts of collagen and other extracellular matrix proteins [10]. Although epithelial cells can transform into mesenchymal cells during embryogenesis, recent studies indicate that this, or the transformation of endothelial cells into mesenchyme, is not the source of the majority of the cells in the fibrotic.